Management of distal ulcerative colitis: Frequently asked questions analysis

Internal Medicine Journal

Volumn 38, Issue 2, 2008, Pages 114-119

  James, S L ^a   Irving, P M ^a   Gearry, R B ^a   Gibson, P R ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b BOX HILL HOSPITAL   (Australia)

Author keywords

Colorectal cancer surveillance; Corticosteroids; Immunemodulator drugs; Inflammatory bowel disease; Iron deficiency; Mesalazine

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; ENEMA; HYDROCORTISONE; INFLIXIMAB; IRON; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISOLONE; PREDNISONE;

BREAST FEEDING; CANCER SCREENING; COLORECTAL CANCER; CONCEPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FOAM; HUMAN; IRON DEFICIENCY; MAINTENANCE THERAPY; MALE FERTILITY; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION ROUTES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MESALAMINE; RECURRENCE;

EID: 39149085678     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01601.x     Document Type: Review

References (35)

1. Regueiro M, Loftus EV Jr., Steinhart AH, Cohen RD. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis 2006 12 : 972 8.
2. Regueiro M, Loftus EV Jr., Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006 12 : 979 94.
3. Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal colitis. Am J Gastroenterol 2000 95 : 1628 36.
4. Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004 16 : 775 8.
5. Meyer AM, Ramzan NN, Loftus EV Jr., Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004 38 : 772 5.
6. Gearry R. Faecal testing in inflammatory bowel disease. In : Fraser A, Gibson PR, Hibi T, Qian J-M, Schomerich J, eds. Emerging Issues in Inflammatory Bowel Disease. Dordrecht, The Netherlands : Springer 2006 135 48.
7. Hommes DW. CMV co-infection - does it matter? In : Irving PM, Rampton DS, Shanahan F, eds. Clinical Dilemmas in Inflammatory Bowel Disease. Oxford : Blackwell Publishing 2006 159 63.
8. Travis SP. Which 5-ASA? Gut 2002 51 : 548 9.
9. Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther 2006 24 (Suppl. 3 37 40.
10. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006 CD 000544.
11. Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PW et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992 339 : 1279 81.
12. Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998 114 : 15 22.
13. Naganuma M, Iwao Y, Ogata H, Inoue N, Funakoshi S, Yamamoto S et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis 2001 7 : 221 5.
14. Kornbluth A, Cuffari C, George J, Legnanai P, Kissous-Hunt M, Fried-Boxt E et al. A prospective blinded assessment of distal colonic mucosal concentrations of 5-ASA and Nac-5-ASA in ulcerative colitis patients treated with balsalazide (Colazal) or pH-dependent mesalamine (Asacol). Gastroenterology 2006 130 (Suppl. 2 A209.
15. Thomson GT, Thomson BR, Thomson KS, Ducharme JS. Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J Rheumatol 2000 27 : 714 18.
16. Pruitt R, Levine DS, Safdi M, Riff D, Hanson J, Wruble L et al. Balsalazide as alternative therapy to mesalamine dose-escalation for acute, mild to moderate ulcerative colitis. Gastroenterology 2002 122 : A499.
17. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006 CD 000543.
18. Hanauer S, Good LI, Goodman MW, Pizinger RJ, Strum WB, Lyss C et al. Long term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000 95 : 1749 54.
19. Kornbluth A, Sacher DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004 99 : 1371 85.
20. Orchard T, Probert CS, Keshav S. Review article: maintenance therapy in patients with ulcerative colitis. Aliment Pharmacol Ther 2006 24 (Suppl. 1 17 22.
21. Timmer A, McDonald J, MacDonald J. Azathioprine and 6-mercaptopurine for maintenance of remission of ulcerative colitis. Cochrane Database Syst Rev 2007 CD 000478.
22. Cummings JR, Herrlinger KR, Travis SP, Gorard DA, McIntyre AS, Jewell DP. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005 21 : 385 9.
23. Nathan DM, Iser JH, Gibson PR. A single centre experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J Gastroenterol Hepatol 2007 in press).
24. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 76.
25. Connell W, Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf 1999 21 : 311 23.
26. Kroser J, Srinivasan R. Drug therapy of inflammatory bowel disease in fertile women. Am J Gastroenterol 2006 101 : S633 9.
27. Gardiner SJ, Gearry RB, Roberts RL, Zhang M, Barclay ML, Begg EJ. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 2006 62 : 453 6.
28. Simren M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Bjornsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002 97 : 389 96.
29. Gibson PR, Newnham E, Barrett JS, Shepherd SJ, Muir JG. Fructose malabsorption and the bigger picture. Aliment Pharmacol Ther 2007 25 : 349 63.
30. Barratt JS, Gibson PR. Clinical ramifications of malabsorption of fructose and other short-chain carbohydrates. Pract Gastroenterol 2007 31 : 51 65.
31. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004 126 : 1634 48.
32. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004 126 : 451 9.
33. Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2004 CD 000279. Review. Update in: Cochrane Database Syst Rev 2006;(2):CD 000279.
34. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004 53 : 1190 97.
35. de Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther 2005 22 : 1097 105.